MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME)
IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patients worldwide
MDNA113’s tumor targeting together with conditional activation provides a highly differentiated and potentially superior approach to current anti-PD-1-IL-2 bispecifics in development
TORONTO, Canada and HOUSTON, TX, USA I April 30, 2025 I Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today presents new pre-clinical data from MDNA113, its first candidate from the BiSKIT (Bifunctional SuperKine ImmunoTherapies) platform, at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois.
“Our MDNA113 program continues to generate encouraging pre-clinical data that underscores its potential as a first-in-class immunotherapy for immunologically cold tumors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “MDNA113 is uniquely differentiated against competing anti-PD-1-IL-2 therapies, with an optimized safety and efficacy profile that leverages its clinically validated pharmacology and novel IL-13 targeting approach. Not only are we observing compelling anti-tumor activity in IL-13Rα2 positive tumors but also signs of enhanced memory that may support durable responses. Commercial interest for bi-specific anti-PD-1 therapies is gaining momentum, with several recent transactions validating this emerging class of immunotherapies with the potential to offer new hope to millions of cancer patients worldwide.”
MDNA113 is based on the Company’s IL-2 and IL-13 Superkine Platforms, the former being used to develop MDNA11, a long-acting IL-2 super agonist, which has demonstrated durable single agent anti-tumor activity in the ongoing Phase 1/2 ABILITY-1 study of patients with advanced solid tumors.
Key highlights from the presentation are:
- Cis-binding maximizes synergy between immune checkpoint blockade and IL-2R activation on the same CD8⁺ T effector cells for optimal tumor cytotoxicity.
- MDNA113 retains PD-1/PDL-1 blockade while exhibiting attenuated IL-2R signaling that is restored upon cleavage by tumor-specific proteases in the tumor microenvironment (TME).
- Preferential tumor localization and retention of MDNA113 in the TME for at least 72 hours in mice implanted with tumors expressing IL-13R⍺2.
- IL-13SK masking of IL-2SK in MDNA113 enhances tolerability and attenuates IL-2SK induced peripheral lymphocyte expansion in mice.
- MDNA113 inhibits MC38/IL-13Rα2 tumor growth in mice and promotes memory response against tumor rechallenge with 100% protection observed with complete responders.
- MDNA113 enhances infiltration of functionally active CD8+ T cells over NK cells & Tregs in different tumor models.
- The combination of MDNA113’s tumor targeting and conditional activation represents a uniquely differentiated and potentially superior alternative to other anti-PD-1-IL-2 bispecifics currently in development.
A copy of the poster and related slide deck are available on the “Scientific Presentations” page of Medicenna’s website.
About MDNA113
MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine with exceptionally high affinity for IL-13Rα2 without binding to the functional IL-13R⍺1. IL-13Rα2 is overexpressed in a wide range of solid tumors, including cold tumors with minimal to no expression in normal tissues. IL-13Rα2 expressing tumors also have abundant matrix metalloprotease in the tumor microenvironment that may efficiently activate MDNA113. IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate cancer, pancreatic cancer, ovarian cancer, liver cancer, breast cancer and brain cancer, with an annual world-wide incidence of over 2 million.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
SOURCE: Medicenna Therapeutics
Post Views: 2,489
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME)
IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patients worldwide
MDNA113’s tumor targeting together with conditional activation provides a highly differentiated and potentially superior approach to current anti-PD-1-IL-2 bispecifics in development
TORONTO, Canada and HOUSTON, TX, USA I April 30, 2025 I Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today presents new pre-clinical data from MDNA113, its first candidate from the BiSKIT (Bifunctional SuperKine ImmunoTherapies) platform, at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois.
“Our MDNA113 program continues to generate encouraging pre-clinical data that underscores its potential as a first-in-class immunotherapy for immunologically cold tumors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “MDNA113 is uniquely differentiated against competing anti-PD-1-IL-2 therapies, with an optimized safety and efficacy profile that leverages its clinically validated pharmacology and novel IL-13 targeting approach. Not only are we observing compelling anti-tumor activity in IL-13Rα2 positive tumors but also signs of enhanced memory that may support durable responses. Commercial interest for bi-specific anti-PD-1 therapies is gaining momentum, with several recent transactions validating this emerging class of immunotherapies with the potential to offer new hope to millions of cancer patients worldwide.”
MDNA113 is based on the Company’s IL-2 and IL-13 Superkine Platforms, the former being used to develop MDNA11, a long-acting IL-2 super agonist, which has demonstrated durable single agent anti-tumor activity in the ongoing Phase 1/2 ABILITY-1 study of patients with advanced solid tumors.
Key highlights from the presentation are:
- Cis-binding maximizes synergy between immune checkpoint blockade and IL-2R activation on the same CD8⁺ T effector cells for optimal tumor cytotoxicity.
- MDNA113 retains PD-1/PDL-1 blockade while exhibiting attenuated IL-2R signaling that is restored upon cleavage by tumor-specific proteases in the tumor microenvironment (TME).
- Preferential tumor localization and retention of MDNA113 in the TME for at least 72 hours in mice implanted with tumors expressing IL-13R⍺2.
- IL-13SK masking of IL-2SK in MDNA113 enhances tolerability and attenuates IL-2SK induced peripheral lymphocyte expansion in mice.
- MDNA113 inhibits MC38/IL-13Rα2 tumor growth in mice and promotes memory response against tumor rechallenge with 100% protection observed with complete responders.
- MDNA113 enhances infiltration of functionally active CD8+ T cells over NK cells & Tregs in different tumor models.
- The combination of MDNA113’s tumor targeting and conditional activation represents a uniquely differentiated and potentially superior alternative to other anti-PD-1-IL-2 bispecifics currently in development.
A copy of the poster and related slide deck are available on the “Scientific Presentations” page of Medicenna’s website.
About MDNA113
MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 Superkine with exceptionally high affinity for IL-13Rα2 without binding to the functional IL-13R⍺1. IL-13Rα2 is overexpressed in a wide range of solid tumors, including cold tumors with minimal to no expression in normal tissues. IL-13Rα2 expressing tumors also have abundant matrix metalloprotease in the tumor microenvironment that may efficiently activate MDNA113. IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate cancer, pancreatic cancer, ovarian cancer, liver cancer, breast cancer and brain cancer, with an annual world-wide incidence of over 2 million.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
SOURCE: Medicenna Therapeutics
Post Views: 2,489
